BOSTON, Sept. 12,
2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.
(Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage
biotechnology company, announced today a 1-for-30 reverse split of
its Common Stock, par value $0.001
("common stock"), effective at 5:00 pm
Eastern time today. Beginning on September 13, 2022, the Company's common stock
will trade on The Nasdaq Capital Market on a split adjusted
basis.
At the Company's annual meeting of stockholders on June 9, 2022, the stockholders approved a
proposal to amend the Company's Certificate of Incorporation to
effect a reverse split of the Company's outstanding common stock at
a ratio in the range of 1-for-5 to 1-for-35 to be determined at the
discretion of our Board of Directors, whereby each outstanding 5 to
35 shares would be combined, converted and changed into 1 share of
Common Stock, to enable the Company to comply with the Nasdaq Stock
Market's continued listing requirements.
Upon effectiveness, the reverse stock split will cause a
reduction in the number of shares of common stock outstanding and
issuable upon the conversion of the Company's outstanding stock
options and warrants in proportion to the ratio of the reverse
split, and will cause a proportionate increase in the conversion
and exercise prices of such stock options and warrants. Any
fraction of a share of Common Stock that would be created as a
result of the Reverse Stock Split will be rounded down to the next
whole share and the stockholder will receive cash equal to the
market value of the fractional share, determined by multiplying
such fraction by the closing sales price of the Company's Common
Stock as reported on Nasdaq on the last trading day before the
Reverse Stock Split becomes effective (on a split-adjusted
basis).
The Company's common stock will continue to trade on The Nasdaq
Capital Market under the symbol "NRBO". The new CUSIP number for
the common stock following the reverse split is 64132R 206.
The number of authorized shares of the Company's common stock
will remain at 100 million, while the number of outstanding shares
will be reduced from approximately 26.7 million to approximately
0.9 million.
Additional information about the reverse stock split can be
found in the Company's definitive proxy statement filed with the
Securities and Exchange Commission on May
18, 2022, a copy of which is also available on the Company's
website under the Investor Relations page.
Investor Relations Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-announces-reverse-stock-split-301622020.html
SOURCE NeuroBo Pharmaceuticals, Inc.